Oxidized Phospholipids on ApoB-100, Platelet Activation and Reactivity, and Long-Term Cardiovascular Outcomes
Arteriosclerosis, Thrombosis, and Vascular Biology · 2025
DOI: 10.1161/atvbaha.125.322347 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Arteriosclerosis, Thrombosis, and Vascular Biology, 2025. Verfasst von Sotirios Tsimikas und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Medicine, Sulpizio Cardiovascular Center, University of California San Diego (S.T., X.Y.). Hauptthemen laut MEDLINE: Apolipoprotein B-100, Blood Platelets, Coronary Artery Disease, Percutaneous Coronary Intervention. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS.
Abstract (Originalsprache)
BACKGROUND: OxPL-apoB (oxidized phospholipids [OxPL] on apoB-100), which include OxPL present on Lp(a) (lipoprotein[a]), are associated with higher cardiovascular risk. Experimental studies suggest that OxPL may influence platelet function. METHODS: This observational study assessed the association of OxPL-apoB with intrinsic and on‑clopidogrel platelet reactivity and long-term cardiovascular events in patients undergoing coronary angiography with or without percutaneous coronary intervention in 2040 patients in the EXCELSIOR trial (Impact of Extent of Clopidogrel-Induced Platelet Inhibition During Elective Stent Implantation on Clinical Event Rate). The association of OxPL-apoB to expression of CD62P, CD41, or PAC-1 levels and intrinsic and on-clopidogrel platelet reactivity to collagen and ADP was determined. The relationship of OxPL-apoB and Lp(a) to myocardial infarction-free survival and all-cause mortality at a median of 7 years was assessed using Cox regression models. RESULTS: Elevated levels of OxPL-apoB were associated with the severity of coronary obstruction, and higher prevalence of prior myocardial infarction, percutaneous coronary intervention, and coronary artery bypass graft surgery. No significant associations were present between OxPL-apoB and intrinsic or on-clopidogrel platelet reactivity or activation of platelet receptors. Analyzed individually in separate multivariable models, both OxPL-apoB (hazard ratio, 1.022 [95% CI, 1.005–1.040]; P =0.010) and Lp(a) (hazard ratio, 1.002 [95% CI, 1.000–1.005]; P =0.032) were associated with worse myocardial infarction-free survival. However, in a joint multivariable model analyzed together, neither OxPL-apoB nor Lp(a) was significant. The optimal cut point for myocardial infarction-free survival for OxPL-apoB was 8 nmol/L (hazard ratio, 1.391 [95% CI, 1.086–1.780]; P =0.009) and for Lp(a) 30 mg/dL (hazard ratio, 1.261 [95% CI, 1.012–1.570]; P =0.038). CONCLUSIONS: In patients undergoing coronary angiography with or without percutaneous coronary intervention, OxPL-apoB was not associated with intrinsic and on-clopidogrel platelet reactivity mediated by collagen or ADP. The association of OxPL-apoB and Lp(a) suggests that the accumulation of OxPL on Lp(a) may be a key determinant of long-term cardiovascular outcomes. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT00457236.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiovascular Medicine, Sulpizio Cardiovascular Center, University of California San Diego (S.T., X.Y.).
- Department of Cardiology and Angiology (A.K., T.N., K.F., C.M.V., F.-J.N., D.W.), Medical Centre, University of Freiburg and Faculty of Medicine, University of Freiburg, Germany.
- Institute of Medical Biometry and Statistics (K.K.), Medical Centre, University of Freiburg and Faculty of Medicine, University of Freiburg, Germany.
- Division of Cardiology, University Hospital of Basel, Switzerland (G.L.).
- Department of Cardiology and Intensive Care Medicine, Klinikum Wuerzburg Mitte, Germany (W.H.).
ORCID-Profile: Sotirios Tsimikas, Alexander Kille, Klaus Kaier, Thomas Nührenberg, Gregor Leibundgut, Franz-Josef Neumann, Dirk Westermann
Förderung
- NHLBI NIH HHS
Zitieren
APA
Tsimikas, S., Kille, A., Kaier, K., Nührenberg, T., Franke, K., Valina, C. M., Yang, X., Leibundgut, G., Neumann, F. J., Westermann, D., & Hochholzer, W. (2025). Oxidized Phospholipids on ApoB-100, Platelet Activation and Reactivity, and Long-Term Cardiovascular Outcomes. Arteriosclerosis, Thrombosis, and Vascular Biology. https://doi.org/10.1161/atvbaha.125.322347
Vancouver
Tsimikas S, Kille A, Kaier K, Nührenberg T, Franke K, Valina CM, et al. Oxidized Phospholipids on ApoB-100, Platelet Activation and Reactivity, and Long-Term Cardiovascular Outcomes. Arteriosclerosis, Thrombosis, and Vascular Biology. 2025. doi:10.1161/atvbaha.125.322347
BibTeX
@article{Tsimikas2025,
author = {Tsimikas, Sotirios and Kille, Alexander and Kaier, Klaus and Nührenberg, Thomas and Franke, Kilian and Valina, Christian M and Yang, Xiaohong and Leibundgut, Gregor and Neumann, Franz-Josef and Westermann, Dirk and Hochholzer, Willibald},
title = {Oxidized Phospholipids on ApoB-100, Platelet Activation and Reactivity, and Long-Term Cardiovascular Outcomes},
journal = {Arteriosclerosis, Thrombosis, and Vascular Biology},
year = {2025},
doi = {10.1161/atvbaha.125.322347}
}
EUVIMED